Data suggest the Nativis Voyager® device is safe for treatment of rGBM.
Nativis, Inc., a clinical stage therapeutic device company developing non-invasive treatments for cancers and other serious diseases, announced the publication of an early feasibility study in CNS Oncology suggesting that the Nativis Voyager device is safe for treatment of Recurrent Glioblastoma (rGBM).
Garni Barhoudarian, MD, principal investigator and neurosurgeon at Pacific Neuroscience Institute and John Wayne Cancer Institute stated, “The Nativis Voyager device is a promising technology that may prove to be a viable addition to the management of Glioblastoma multiforme (GBM) and other brain cancers. Led by our team at the John Wayne Cancer Institute, we continue to investigate the potential benefits of this technology in a larger group of patients with both new and recurrent glioblastoma.”
The publication of the study, An Early Feasibility Study of the Nativis Voyager® Device in Patients with Recurrent Glioblastoma is the first cohort in US.
“We are excited to have this publication accepted by CNS Oncology in conjunction with our internationally recognized clinical trial partners, led by Charles Cobbs, MD and Santosh Kesari, MD PhD,” stated Chris Rivera, Nativis Chief Executive Officer. “The data in this early feasibility study not only suggest that the Nativis Voyager device is safe for the treatment of rGBM, but also that further studies to explore clinical utility are warranted.”
The Nativis Voyager produces ultra-low radio frequency energy (ulRFE®) intended to induce a biologic response in solid tumors, such as rGBM. The ulRFE cognate is created by measuring and recording the oscillating magnetic field produced by molecules in solution. The recorded cognate is then used to reproduce the recorded magnetic field using an electromagnetic coil worn externally on the head by the patient.
“Nativis is grateful to our clinical partners, patients, and their families in this effort to develop an effective treatment for one of the most difficult diseases to treat known to medical science.” Rivera went on to state, “Without the efforts of our dedicated and extraordinary clinical partners, our patients and their families would have fewer hopes to address the devastating effects of rGBM.”
Rivera concluded, “We are looking forward to obtaining data from this ongoing clinical study for treatment of rGBM, with the expectation of producing safety and clinical utility results that are encouraging for our patients and their families.”
For more information about clinical trials at Pacific Neuroscience Institute, contact us at 310-829-8265 or view brain tumor clinical trials listings.